AR110057A1 - Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash) - Google Patents

Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash)

Info

Publication number
AR110057A1
AR110057A1 ARP170103142A ARP170103142A AR110057A1 AR 110057 A1 AR110057 A1 AR 110057A1 AR P170103142 A ARP170103142 A AR P170103142A AR P170103142 A ARP170103142 A AR P170103142A AR 110057 A1 AR110057 A1 AR 110057A1
Authority
AR
Argentina
Prior art keywords
nafld
nash
treatment
pirfenidone
esteatohepatitis
Prior art date
Application number
ARP170103142A
Other languages
English (en)
Spanish (es)
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Publication of AR110057A1 publication Critical patent/AR110057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP170103142A 2016-11-11 2017-11-10 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash) AR110057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Publications (1)

Publication Number Publication Date
AR110057A1 true AR110057A1 (es) 2019-02-20

Family

ID=61193005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103142A AR110057A1 (es) 2016-11-11 2017-11-10 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash)

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
CL2019001280A1 (es) 2019-07-19
KR20190084056A (ko) 2019-07-15
IL266519A (en) 2019-07-31
AU2024200737A1 (en) 2024-02-22
JP2019535822A (ja) 2019-12-12
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
MX364040B (es) 2019-04-11
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
RU2019116422A (ru) 2020-12-11
AU2017358367B2 (en) 2023-11-09
US20250325530A1 (en) 2025-10-23
JP2022173344A (ja) 2022-11-18
CA3043300A1 (en) 2018-05-17
CN110248646A (zh) 2019-09-17
US20230181550A1 (en) 2023-06-15
ECSP19031851A (es) 2019-06-30
MA45754A1 (fr) 2019-12-31
US20190262325A1 (en) 2019-08-29
PE20191149A1 (es) 2019-09-02
JOP20190102A1 (ar) 2019-05-06
RU2019116422A3 (enExample) 2021-04-09
CN115969802A (zh) 2023-04-18
WO2018088886A1 (es) 2018-05-17
CO2019004799A2 (es) 2019-07-31
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX2016014775A (es) 2018-05-10

Similar Documents

Publication Publication Date Title
AR110057A1 (es) Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash)
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
LU92578B1 (fr) Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
LU92577B1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
HRP20190573T1 (hr) Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti
EP3113764A4 (en) Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof
IL272457A (en) GLP-1/Glucagon agonist receptors in the treatment of fatty liver disease and steatohepatitis
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
IL245429B (en) A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases
PE20200444A1 (es) Terapia de combinacion para cancer de prostata
EP2949333A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THERMAL INJURIES AND WOUNDS COMBINED WITH BONE LESIONS
EP3290034A4 (en) Use of trimethazine in preparation of drugs for preventing and treating liver diseases
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL249440A0 (en) Compounds, pharmaceutical preparations and their use in the treatment of neurodegenerative diseases
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización
RU2015122823A (ru) Способ лечения печёночной энцефалопатии у больных циррозом печени
BR112018016725A2 (pt) composição farmacêutica para prevenir e tratar transtornos do sono

Legal Events

Date Code Title Description
FB Suspension of granting procedure